New substituted triazolopyrimidne derivatives were synthesized starting from 1,2,3-triazolo-4-carboxamide derivative. The N- and S-glycoside derivatives of the synthesized triazolopyrimidine ring system as well as their acyclic sugar analogs were also synthesized. The cytotoxicity and in vito anticancer evaluation of the prepared compounds have been assessed against three different human tumor cell lines including human breast MCF-7, lung A549 and colon HCT116 cancer cell lines. The results revealed that the prepared compounds exert their actions in MCF-7 and A549. MCF-7 cells are more sensitive to the tested compounds than the other cell lines. Compounds 2, 3, 9 and 10 revealed promising anticancer activities compared to the activity of the commonly used anticancer drug, doxorubicin in both MCF-7 and A549 cell lines.